1. Search Result

Search Result

Results for "productlist/W" in MCE Product Catalog:

36

Inhibitors & Agonists

2

Peptides

4

Natural
Products

Cat. No. Product Name Target Research Area
  • HY-16992A
    W-54011

    Complement System Reactive Oxygen Species Inflammation/Immunology
    W-54011 is a potent and orally active non-peptide C5a receptor antagonist. W-54011 inhibits the binding of 125I-labeled C5a to human neutrophils with a Ki value of 2.2 nM. W-54011 also inhibits C5a-induced intracellular Ca 2+ mobilization, chemotaxis, and generation of ROS in human neutrophils with IC50s of 3.1 nM, 2.7 nM, and 1.6 nM, respectively.
  • HY-100174
    W-2429

    NSC294836

    Others Neurological Disease
    W-2429 is a non-narcotic analgesic agent.
  • HY-101395
    W146

    W-146; W 146

    LPL Receptor Cancer Metabolic Disease
    W146 is a selective antagonist of sphingosine-1-phosphate receptor 1 (S1PR1) with an EC50 value of 398 nM.
  • HY-18731
    1400W Dihydrochloride

    NO Synthase Inflammation/Immunology Cardiovascular Disease Cancer
    1400W dihydrochloride is a potent and selective inhibitor of human inducible NO synthase with Ki values of 7 nM.
  • HY-19282A
    (5R)-BW-4030W92

    Others Others
    (5R)-BW-4030W92 is the R enantiomer of BW-4030W92. BW-4030W92 is a non-selective, voltage-, and use-dependent sodium channel antagonist.
  • HY-B0184
    Felbamate

    W-554; ADD-03055

    iGluR Neurological Disease
    Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).
  • HY-19264
    264W94

    Others Metabolic Disease
    264W94 is a potent ileal bile acid transporter (IBAT) inhibitor and a new cholesterol lowering agent. 264W94 has CYP7A1 induction, and antilipemic action.
  • HY-U00157
    Meseclazone

    W2395; NSC297623

    Others Inflammation/Immunology
    Meseclazone (W2395;NSC297623) exhibits inhibitory potency of secondary phase ADP aggregation. Meseclazone possesses anti-inflammatory, analgesic and antipyretic activity.
  • HY-101578
    2614W94

    Monoamine Oxidase Neurological Disease
    2614W94 is a selective, reversible inhibitor of monoamine oxidase-A with a competitive mechanism of inhibition and IC50 of 5 nM and Ki of 1.6 nM with serotonin as substrate.
  • HY-107094
    MT-7716 hydrochloride

    W-212393 hydrochloride

    Opioid Receptor Neurological Disease
    MT-7716 hydrochloride (W-212393 hydrochloride) is a selective non-peptide nociceptin receptor (NOP) agonist and promising potential treatment drug for alcohol abuse and relapse prevention.
  • HY-107094A
    MT-7716 free base

    W-212393

    Opioid Receptor Neurological Disease
    MT-7716 free base (W-212393) is a selective non-peptide nociceptin receptor (NOP) agonist and promising potential treatment drug for alcohol abuse and relapse prevention.
  • HY-B0674
    Ebastine

    LAS-W 090; RP64305

    Histamine Receptor Inflammation/Immunology Endocrinology
    Ebastine(LAS-W 090;RP64305) is a long-acting and selective H1-histamine receptor antagonist.
  • HY-13596
    Cisatracurium besylate

    51W89

    nAChR Autophagy Neurological Disease Cancer
    Cisatracurium besylate (51W89) is a nondepolarizing neuromuscular blocking agent, antagonizing the action of acetylcholine by inhibiting neuromuscular transmission.
  • HY-B0184A
    Felbamate hydrate

    W-554 hydrate; ADD-03055 hydrate

    iGluR Neurological Disease
    Felbamate hydrate (W-554 hydrate) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA) .
  • HY-14144
    Aclidinium Bromide

    LAS 34273; LAS-W 330

    mAChR Inflammation/Immunology
    Aclidinium Bromide(LAS 34273; LAS-W 330) is a long-acting, inhaled muscarinic antagonist as a maintenance treatment for chronic obstructive pulmonary disease (COPD).
  • HY-13458
    Droxidopa

    L-DOPS; DOPS; SM5688

    Others Neurological Disease
    Droxidopa(L-DOPS), the mixture of Droxidopa (w/w80%) and Pharmaceutical starch (w/w20%), acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline); Droxidopa(L-DOPS) is capable of crossing the protective blood–brain barrier.
  • HY-B1012
    Quinestrol

    W-3566

    Estrogen Receptor/ERR Endocrinology Cancer
    Quinestrol is a synthetic estrogen, used in hormone replacement therapy, and occasionally to treat breast cancer and prostate cancer
  • HY-10852
    Arterolane

    OZ 277; RBx 11160

    Parasite Infection
    Arterolane is an antimalarial agent, with IC50 of both 1.1 nM against P. falciparum Ro73 and W2, respectively.
  • HY-W043277
    m-PEG3-Tos

    PROTAC Linker Cancer
    m-PEG3-Tos is a PEG-based PROTAC linker can be used in the synthesis of Silymarin (HY-W043277).
  • HY-16305
    Maribavir

    1263W94; BW1263W94; GW257406X

    CMV Infection
    Maribavir is a potent inhibitor of histone phosphorylation catalyzed by wild-type pUL97 in vitro, with an IC50 of 3 nM. Maribavir has potent antiviral activity against HCMV and Epstein-Barr virus (EBV).
  • HY-50907
    ABT-737

    Bcl-2 Family Autophagy Mitophagy Cancer
    ABT-737 is a selective and BH3 mimetic Bcl-2, Bcl-xL and Bcl-w inhibitor with EC50s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively.
  • HY-15975
    GNF179

    Parasite Infection
    GNF179 is an optimized 8,8-dimethyl IP analog that exhibited the potency(4.8 nM against the multidrug resistant strain W2) in vitro metabolic stability and in vivo oral bioavailability.
  • HY-B1108
    Labetalol hydrochloride

    AH-5158 hydrochloride; Sch-15719W

    Adrenergic Receptor Cardiovascular Disease Endocrinology
    Labetalol hydrochloride is a mixed alpha/beta adrenergic antagonist that is used to treat high blood pressure.
  • HY-114661
    m-PEG4-Tos

    PROTAC Linker Cancer
    m-PEG4-Tos is a derivative of silybin ethers, extracted from patent CN105037337A (compound III-b). m-PEG4-Tos is a PEG-based PROTAC linker can be used in the synthesis of Silymarin (HY-W043277).
  • HY-108294
    Nonaethylene glycol monododecyl ether

    Nonaoxyethylene monododecyl ether

    Others Others
    Nonaethylene glycol monododecyl ether (Nonaoxyethylene monododecyl ether) is a nonionic surfactant and polyethylene glycol (PEG) detergent that can be used to form initial coalesced O/W emulsion droplets, as well as for protein separation and purification.
  • HY-W042501
    m-PEG5-Tos

    PROTAC Linker Cancer
    m-PEG5-Tos is a derivative of silybin ethers, extracted from patent CN105037337A (compound III-c). m-PEG5-Tos is a PEG-based PROTAC linker can be used in the synthesis of Silymarin (HY-W043277).
  • HY-15980
    GNF179 Metabolite

    Parasite Infection
    GNF179 metabolite is the metabolite of GNF179, which is an optimized 8,8-dimethyl IP analog that exhibited the potency(4.8 nM against the multidrug resistant strain W2) in vitro metabolic stability and in vivo oral bioavailability.
  • HY-10087
    Navitoclax

    ABT-263

    Bcl-2 Family Cancer
    Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM.
  • HY-19702
    PKR-IN-2

    Others Cancer
    PKR-IN-2 is a pyruvate kinase (PKR) activator, extracted from patent WO2014139144A1, compound 160, has an IC50 of <100 nM for. PKR (R510Q), PKR (R532W), PKR (WT), and PKR (WT Cell Based).
  • HY-135090
    m-PEG8-Tos

    PROTAC Linker Cancer
    Tos-PEG8-m is a derivative of silybin ethers, extracted from patent CN105037337A (compound III-d). Tos-PEG8-m is a PEG-based PROTAC linker can be used in the synthesis of Silymarin (HY-W043277).
  • HY-N0674
    Dehydrocorydaline

    13-Methylpalmatine

    Bcl-2 Family Caspase PARP Cancer
    Dehydrocorydaline (13-Methylpalmatine) is an alkaloid isolated from traditional Chinese herb Corydalis yanhusuo W.T. Wang. Dehydrocorydaline regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates PARP.
  • HY-N6009
    8-Deoxygartanin

    Parasite NF-κB Infection
    8-Deoxygartanin, a prenylated xanthones from G. mangostana, is a selective inhibitor of butyrylcholinesterase (BChE). 8-Deoxygartanin exhibits antiplasmodial activity with an IC50 of 11.8 μM for the W2 strain of Plasmodium falciparum. 8-Deoxygartanin inhibits NF-κB (p65) activation with an IC50 of 11.3 μM.
  • HY-N0087
    Gambogic Acid

    Beta-Guttiferrin

    Bcl-2 Family Autophagy Cancer
    Gambogic Acid (Beta-Guttiferrin) is derived from the gamboges resin of the tree Garcinia hanburyi. Gambogic Acid (Beta-Guttiferrin) inhibits Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1 with IC50s of 1.47 μM, 1.21 μM, 2.02 μM, 0.66 μM, 1.06 μM and 0.79 μM.
  • HY-135855
    SARS-CoV-IN-1

    SARS-CoV Parasite Infection
    SARS-CoV-IN-1 is an effective inhibitor of SARS-CoV replication. SARS-CoV-IN-1 shows anti-Coronavirus activity with an EC50 of 4.9 μM in Vero cells. SARS-CoV-IN-1 inhibits the 3D7 and W2 strains of P. falciparum with IC50s of 15.4 and 133.2 nM; and IC90s of 25.7 and 459.1 nM; respectively. Antimalarial and antiviral activities.
  • HY-135858
    SARS-CoV-IN-3

    SARS-CoV Parasite HIV Infection
    SARS-CoV-IN-3 is an effective inhibitor of SARS-CoV replication. SARS-CoV-IN-3 shows anti-Coronavirus activity with an EC50 of 3.6 μM in Vero cells. SARS-CoV-IN-3 inhibits the 3D7 and W2 strains of P. falciparum with IC50s of 11.7 and 20.4 nM; and IC90s of 29.19 and 56 nM; respectively. SARS-CoV-IN-3 reduces HIV-1-induced cytopathic effect with an EC50 of 10 μM in MT-4 cells.
  • HY-135856
    SARS-CoV-IN-2

    SARS-CoV Parasite HIV Infection
    SARS-CoV-IN-2 is an effective inhibitor of SARS-CoV replication. SARS-CoV-IN-2 shows anti-Coronavirus activity with an EC50 of 1.9 μM in Vero cells. SARS-CoV-IN-2 inhibits the 3D7 and W2 strains of P. falciparum with IC50s of 21.5 and 30 nM; and IC90s of 51.0 and 99.9 nM; respectively. SARS-CoV-IN-2 reduces HIV-1-induced cytopathic effect with an EC50 of 2.9 μM in MT-4 cells. Antimalarial and Antiviral Activities.